Biolyst › MDWDMediWound Ltd. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Medicinal Chemicals & Botanical Products.
The next scheduled catalyst is A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) on December 15, 2026. There are 3 upcoming events on record.
Cash runway is approximately 2.5 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 9 concluded trials, 89% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
December 15, 2026
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) Trial Milestone
Phase 3
August 15, 2028
An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers Trial Milestone
Phase 2
November 4, 2028
A Multicenter, Prospective, Randomized, Placebo and Non-Surgical Standard of Care (NSSOC) Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to NSSOC in Participants With Venous Leg Ulcers (VLU) Trial Milestone
Phase 2
Track MDWD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MDWD in the tracker
Recent history
Date Event Type Phase
August 13, 2026
6-K filed: Foreign issuer report Filing
—
May 27, 2026
6-K filed: Foreign issuer report Filing
—
May 6, 2026
6-K filed: Foreign issuer report Filing
—
April 2, 2026
6-K filed: Foreign issuer report Filing
—
March 30, 2026
6-K filed: Foreign issuer report Filing
—
March 5, 2026
6-K filed: Foreign issuer report Filing
—
March 5, 2026
Results filed (20-F) Earnings
—
February 19, 2026
6-K filed: Foreign issuer report Filing
—
January 15, 2026
6-K filed: Foreign issuer report Filing
—
January 12, 2026
6-K filed: Foreign issuer report Filing
—
November 20, 2025
6-K filed: Foreign issuer report Filing
—
September 30, 2025
6-K filed: Foreign issuer report Filing
—
September 29, 2025
6-K filed: Foreign issuer report Filing
—
August 19, 2025
6-K filed: Foreign issuer report Filing
—
August 14, 2025
6-K filed: Foreign issuer report Filing
—
May 21, 2025
6-K filed: Foreign issuer report Filing
—
May 15, 2025
6-K filed: Foreign issuer report Filing
—
May 15, 2022
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma Trial Milestone
Phase 1/Phase 2
May 6, 2022
A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers Trial Milestone
Phase 2
December 7, 2021
A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers Trial Milestone
Phase 2
April 15, 2021
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care Trial Milestone
Phase 3
June 12, 2018
A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns Trial Milestone
Phase 3
December 5, 2017
Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds Trial Milestone
Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.